Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 3 1Phase 2 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4Genitourinary 1Dermatologic 1

Conditions

Melanoma 22Carcinoma, Renal Cell 19HIV Infections 6Acquired Immunodeficiency Syndrome 6Sarcoma, Kaposi 5Leukemia 5Neoplasm Metastasis 4Lymphoma 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Triple Negative Breast Neoplasms 3Recurrence 3Neoplasms 3Kidney Neoplasms 3Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Leukemia, Myeloid, Chronic-Phase 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Thrombocythemia, Essential 1Solid Cancers 1

Interventions

Imatinib Mesylate 142nilotinib 94Cyclophosphamide 91fludarabine phosphate 75fludarabine 67Dasatinib 63Mycophenolic Acid 60Whole-Body Irradiation 59Tacrolimus 47Busulfan 45Cyclosporine 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 35Melphalan 30bosutinib 27ponatinib 26Granulocyte Colony-Stimulating Factor 26thymoglobulin 25Thiotepa 25Methotrexate 25Filgrastim 25asciminib 24Antilymphocyte Serum 24Stem Cell Transplantation 22Sirolimus 17Interferon-alpha 16sargramostim 15Cord Blood Stem Cell Transplantation 14Clofarabine 13Bone Marrow Transplantation 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Interferon alpha-2 × Clear all
NCT03547154 2019-08-12

C98026

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
344 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Hoffmann-La Roche

Phase 2/3 Completed
9 enrolled 7 charts
DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00050531 2016-05-11

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

M.D. Anderson Cancer Center

Phase 3 Completed
94 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00003239 2012-07-30

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

M.D. Anderson Cancer Center

Phase 2 Completed
90 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡